

Examination of the Effect of the Active Pharmaceutical Ingredient (API) on Pathogenic Bacteria in the Oral Cavity

Glucodent Ltd. has successfully completed the examination of the effect of the API on the growth and development (proliferation) of pathogenic bacteria in the oral cavity.

The oral cavity of a person with diabetes contains a significantly higher number of pathogenic bacteria compared to healthy individuals, leading to higher concentrations of acids, inflammatory processes, bleeding, and other symptoms, which, according to scientific publications, directly further deteriorate the health condition of diabetics.

Glucodent Ltd. has successfully conducted scientific examinations of the API's effect on the concentrations of pathogenic bacteria in the oral cavity. Analysis of the results revealed a strong antibacterial activity of the API.

This test confirms the quality of the scientific research that served as the foundation for the development of the medical product. This process concludes one of the key parts of laboratory testing, which is the basis for creating the clinical protocol and beginning clinical trials on humans.

Glucodent Ltd. introduces an advanced research and development project focused on creating a specialized product for oral pathology intended for people with diabetes. Our mission is to improve the oral health and well-being of diabetics through an innovative and scientifically validated product.

The project relies on the expertise of leading scientific institutions and our distinguished team of scientists. Additionally, we collaborate with experts in key areas such as intellectual property (IP), legal affairs, regulatory compliance, and strategic consulting. This comprehensive approach ensures that our product not only achieves efficacy but also meets the highest quality standards.